The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists

Michaël J. B. van Baar, Annemarie B. van der Aart, Klaas Hoogenberg, Jaap A. Joles, Hiddo J. L. Heerspink, Daniël H. van Raalte

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Diabetic kidney disease (DKD) remains the main cause for chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide. Both CKD and ESKD lead to major increases in risk of cardiovascular disease and death in people with diabetes. Despite optimal management of lifestyle, glucose levels and hypertension, residual risk remains high, indicating that additional therapies to mitigate the burden of the disease are desired. In past decades, new treatment options for the management of diabetes have emerged, of which some have showed promising renoprotective potential. This review discusses current understanding of the renal effects of glucagon-like peptide receptor agonists and their potential use in prevention and treatment of DKD.
Original languageEnglish
JournalTherapeutic Advances in Endocrinology and Metabolism
Volume10
DOIs
Publication statusPublished - 2019

Cite this